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Conclusion: new parameters were found as predictors of 
moderate-severe mucositis. 
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Purpose or Objective: Retrospective review of results of 
radiotherapy for stage T1 glottic carcinoma. 
 
Material and Methods: A retrospective review was done of 
all patients with squamous cell carcinoma of the glottis stage 
T1 treated with radiotherapy between 1960 and 2012 
inclusive. There were 995 patients identified. All patients 
were treated with wedged lateral or angled anterior oblique 
technique. The main site of relapse was local and hence the 
main end point for anaysis was local control at 5 years. 
Survival curves were calculated using Kaplan Meier method 
and log rank test used to comparer differences. 
 
Results: Overall the 5 year freedom from relapse was 88%. 
The only factor which influenced outcome was time period of 
radiotherapy with those between 1960 and 1980 had a 84% 
relapse free rate, significantly worse than the latter time 
period. Other factors examined included sex, age, substage 
T1a and T1b, grade, radiation dose, radiation field size and 
duration of radiation, and none of those factors had a 
significant effect on outcome. There were 121 relapses, most 
in the primary alone and most within the first two years.  
 
Conclusion: The overall 5 year freedom from relapse was 
88%. 
 
EP-1037  
Dysphagia and irradiation of constrictor pharyngeal 
muscles: a clinical-dosimetric correlation 
F. Deodato
1Fondazione di Ricerca e Cura “Giovanni Paolo II”- Catholic 
University of Sacred Heart, Radiation Oncology Unit, 
Campobasso, Italy 
1, S. Cilla2, F. Grifa1, G. Macchia1, G. Sallustio3, M. 
Nuzzo1, M. Ferro1, F. Labropoulos1, S. Mignogna4, B. Corvari5, 
F. Marazzi5, A. Veraldi6, M. Pieri6, S. Ciabatti6, U. Caliceti7, S. 
Cammelli6, G. Frezza8, V. Valentini5, A.G. Morganti6 
2Fondazione di Ricerca e Cura “Giovanni Paolo II”- Catholic 
University of Sacred Heart, Medical Physics Unit, 
Campobasso, Italy 
3Fondazione di Ricerca e Cura “Giovanni Paolo II”- Catholic 
University of Sacred Heart, Radiology Unit, Campobasso, 
Italy 
4Fondazione di Ricerca e Cura “Giovanni Paolo II”- Catholic 
University of Sacred Heart, Oncology Unit, Campobasso, Italy 
5Policlinico Universitario “A. Gemelli”- Catholic University of 
Sacred Heart, Department of Radiotherapy, Roma, Italy 
6S. Orsola-Malpighi Hospital- University of Bologna, Radiation 
Oncology Center- Department of Experimental- Diagnostic 
and Specialty Medicine – DIMES, Bologna, Italy 
7S. Orsola-Malpighi Hospital- University of Bologna, Unit of 
Otolaryngology- Department of Specialist Surgery and 
Anesthesiology, Bologna, Italy 
8Bellaria Hospital, Radiotherapy Department, Bologna, Italy 
 
Purpose or Objective: To correlate clinical late dysphagia 
with the dose received by the constrictor pharyngeal muscles 
in patients receiving induction chemotherapy (ICT) and 
radiochemotherapy (RT-CT) with SIB-VMAT technique. 
 
Material and Methods: Between July 2010 and January 2015, 
51 patients with locally advanced head and neck cancer 
underwent ICT and subsequent RT-CT with concurrent weekly 
Cisplatin. The superior, middle, and inferior (S, M, and I) 
pharyngeal constrictors muscles (CM) were delineated and 
the correlation between dosimetric parameters and late 
pharyngeal toxicity was analyzed. 
 
Results: 51 patients [M/F: 41/10, median age 56, range 30-
77, stage III: 10 (20%), stage IV: 41 (80 %)] were included in 
this analysis. The tumor site was: oropharynx in 21 (40%) 
patients, epipharynx in 10 (20%), oral cavity in 9 (18%), larynx 
in 5 (10%), and hypopharynx in 6 (12%). ICT in the majority of 
cases (74%), was based on Cisplatin - 5 -Fluorouracil, with the 
addition of Docetaxel in 26% of cases. The dose delivered to 
the primary tumor was 67.5 Gy (in 8 patients, 16 %) and 70.5 
Gy (in 43 patients, 84 %); 60 Gy and 55.5 Gy were delivered 
on high and low risk lymph node levels, in 30 fractions with 
SIB-VMAT (2 arcs) technique, respectively. With a median 
follow-up of 11 months (range 3-44), late G1 dysphagia was 
recorded in 6 patients (12%) and late G2 dysphagia was 
observed in 2 patients (4%) (CTC-AE v. 4.3). Other late 
toxicities are reported in the Table 1. G3-4 toxicities were 
not recorded. In DVH analysis, the median dose received by 
CM was 66.2 Gy (S: 67.4 Gy, M and I: 67.2 Gy), with V50 being 
96.9 % (S: 97.4%, M: 98.3%, and I: 95.9 %), and V60 being 
82.4% (S: 86.8%, M: 90.1 %, and I: 73.8%). The median dose 
received by the larynx was 63.5 Gy (V50: 94.1 %, and V60: 
66.2 %). No statistically significant difference between the 
group of patients with and without late dysphagia was 
observed. 
 
 
 
Conclusion: No statistically significant correlation between 
dose delivered to the constrictors muscles and late dysphagia 
was observed in this patients cohort. This result may depend 
on tolerability of the treatment and then by the small 
number of recorded adverse events. 
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Purpose or Objective: To evaluate the toxicity of intensity 
modulated radio-chemotherapy with simultaneous integrated 
boost technique (SIB) after induction chemotherapy in 
patients with locally advanced head and neck (H&N) cancer. 
 
Material and Methods: The IRMA studies are described in the 
table. Patients with stage III-IV H&N cancer, without 
progressive disease after induction chemotherapy (IC), 
underwent radio-chemotherapy with weekly Cisplatin 30 
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mg/m2 (IRMA 1, 2, 3, 5) or Cetuximab 400 mg/m2 (IRMA 4). A 
dose of 67.5 Gy in 30 fractions (IRMA 1, 2, and 4) or 70.5 Gy 
in 30 fractions (IRMA 3, 4, and 5) was delivered to primary 
tumor and involved nodes, 60 Gy were delivered to high risk 
and 55.5 Gy to low risk lymph node areas. Static (IMRT) or 
volumetric (VMAT) intensity modulated technique with 
simultaneous integrated boost was used. 
 
Results: 107 patients (median age 56 years, range 30-78, 
UICC stage III: n = 18, IV: n = 89) were included in this 
analysis. IC was performed with Cisplatin + 5-Fluorouracil in 
65 (61%) patients and with Docetaxel + Cisplatin + 5-
Fluorouracil in 42 (39%) cases. Concomitant Cisplatin and 
Cetuximab were administered in 84% and in 16% of patients, 
respectively. 51% (n = 55) of cases were irradiated with step 
& shoot IMRT-SIB technique (7 beams), while 49% (n = 52) of 
patients were irradiated with VMAT-SIB (two arcs) technique. 
During radio-chemotherapy, 23 (21%) patients developed 
mucositis, 12 (11%) G3 dysphagia and 10 (9.3%) G3 
hematological toxicity. Even 1 (0.9%) G4 leukopenia and 3 
(2.8%) G5 (2 neutropenia and one fatal myocardial infarction) 
adverse events were observed. The overall response rate 
after radio-chemotherapy was 82.2%. Two-year local control 
and survival were 64.2% and 64.6% (IRMA 1), respectively, 
57.8% and 56.2% (IRMA 2), 66.4% and 75.5% (IRMA 3), 70.1% 
and 66.7% (IRMA 4), and 76.5% and 82.4% (IRMA 5), 
respectively. 
 
 
 
Conclusion: In our experience moderately hypofractionated 
and accelerated radio-chemotherapy after induction 
chemotherapy was feasible. Intensive patient monitoring and 
supportive strategies during chemoradiation are necessary to 
manage of side effects. 
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Purpose or Objective: To analyse the frequency and severity 
of dysphagia and xerostomia in patients affected by 
nasopharyngeal and oropharyngeal cancers treated by 
intensity-modulated radiotherapy (IMRT) and the correlation 
with volumetric variations and dosimetric data of pharyngeal 
constrictor muscles and parotid glands.  
 
Material and Methods: Fifty patients, who underwent 
adaptive IMRT for nasopharyngeal and oropharyngeal cancers, 
were included in the present study. Eighty-four percent of 
patients (42/50) received concurrent radio-chemotherapy 
and 92% (44/50) were in locally advanced stage. Dose-volume 
parameters related to constrictor muscles (superior 
constrictor muscle, SCM; middle constrictor muscle, MCM; 
inferior constrictor muscle, ICM and whole pharyngeal 
constrictor muscle, CM), and parotid glands were analyzed 
using dose-volume histograms (DVHs). All patients underwent 
replanning CT scan after 5 weeks of radiation therapy and 
the target and OARs were re-contoured on fusion images 
after co-registration. The volumetric variations of pharyngeal 
constrictor muscles and parotid glands were measured. 
Volumetric variations and dose-volume parameters were 
associated to acute and late dysphagia and xerostomia 
according to RTOG score, quality of life questionnaires (PSS-
H&N e QLQ-H&N35), and oesophageal transit . 
 
Results: Volumetric variations and dose-volume parameters 
of pharyngeal constrictor muscles and parotid glands are 
reported in Table 1. Adaptive IMRT achieved a good sparing 
of parotid glands (mean dose 24.9 Gy) and constrictor 
muscles (mean dose 51.2 Gy). Acute dysphagia, was scored as 
grade 0-1 in 18/50 patients (36%) and as grade 2-3 in 32/50 
(64%). Acute xerostomia, was scored as grade 0-1 in 21/50 
patients (42%) and as grade 2-3 in 29/50 (58%). Volumetric 
variations and dose-volume parameters of the constrictor 
muscles and parotid glands did not correlate with acute 
toxicity (p>0.05). At 2 years median follow-up (range 6-67 
months), late dysphagia was scored as grade 0-1 in 40/50 of 
patients (80%) and as grade 2-3 in 10/50 (20%). Late 
xerostomia was scored as grade 0-1 in 42/50 of patients (84%) 
and as grade 2-3 in 8/50 (16%). The analysis of the 
correlation of volumetric variations and dose-volume 
parameters with clinical data (RTOG score for late toxicity, 
quality of life questionnaires and oesophageal transit) is 
ongoing. 
 
 
 
Conclusion: During radiotherapy, pharyngeal constrictor 
muscles and salivary glands underwent volumetric variations. 
Volumetric variations and dosimetric findings did not 
correlate with acute toxicity, probably because of the 
complexity and multifactorial pathogenesis of acute 
dysphagia and xerostomia. The ongoing analysis on the 
correlation of late toxicity data with volumetric variations 
and dose-volume parameters may help in the optimization of 
IMRT treatment planning. 
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